Last reviewed · How we verify

NCT05410990

Eosinophil Indices in Patients With Acute Heart Failure

Completed Last updated 8 June 2022
What this trial tests

trial testing eosinophil and other hematological parameters in Acute Heart Failure in 395 participants. Completed in 5 April 2022.

Timeline
2 January 2017
Primary endpoint
30 December 2021
5 April 2022

Quick facts

Lead sponsorGiresun University
StatusCompleted
Study typeOBSERVATIONAL
Enrollment395
Start date2 January 2017
Primary completion30 December 2021
Estimated completion5 April 2022

Drugs / interventions tested

Conditions studied

Sponsor

Giresun University

Who can join

Adults 18 to 90, any sex, with Acute Heart Failure or Reduced Systolic Function. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

All consecutive patients admitted to the intensive care unit (ICU) with ADHF between January 2017 and December 2021 were enrolled in this retrospective study. All-cause mortality and MACE were assessed with respect to relationships with eosinophil indices, including neutrophil-to-eosinophil ratio (NER), leukocyte-to-eosinophil ratio (LER), eosinophil-to-lymphocyte ratio (ELR), and eosinophil-to-monocyte ratio (EMR).

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Acute Heart Failure

Currently open trials in the same condition.

Other Giresun University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05410990.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing